secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001193125-22-304330
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports positive KT-474 Phase 1 data; Sanofi advances to Phase 2; oncology programs show target knockdown
--------------------------------------------------------------------------------

- KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.
- Sanofi committed to Phase 2 trials for KT-474 in HS and AD, with first study starting in 2023.
- KT-413 (IRAKIMiD) showed up to 100% Ikaros/Aiolos knockdown and 40% IRAK4 knockdown at dose level 2; no DLTs.
- KT-333 (STAT3) showed mean 66% STAT3 degradation (up to 86%) in PBMC at dose level 1; dose level 2 enrolling.
- FDA cleared IND for KT-253 (MDM2 degrader); Phase 1 planned for early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/0001193125-22-304330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522304330/d429465d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-304330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer